In their recent report on the results of a clinical trial on effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on microcirculation perfusion and tissue oxygenation in patients undergoing liver surgery, Cui and co-workers [1] concluded that for patients undergoing major abdominal surgeries that entail a large amount of blood loss, using HES 130/0.4 for volume replacement treatment may have potential benefit in internal organ perfusion. In support of this conclusion, two studies from Boldt and co-workers have been cited (reference 3 and 4; reference 3 is cited a second time as reference 16) which have been retracted in 2011 because of scientific fraud [2,3]. These citations and the misleading referencing need to be corrected.
Disclosure of conflict of interest
CJW has received fees for speaking at industry symposia from CSL Behring and Baxter.
References
- 1.Cui Y, Sun B, Wang C, Liu S, Li P, Shi J, Li E. Effects of different types of hydroxyethyl starch (HES) on microcirculation perfusion and tissue oxygenation in patients undergoing liver surgery. Int J Clin Exp Med. 2014;7:631–639. [PMC free article] [PubMed] [Google Scholar]
- 2.Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery: Retraction. Anesth Analg. 2011;112:1211. doi: 10.1213/ANE.0b013e31821a96af. [DOI] [PubMed] [Google Scholar]
- 3.Miller DR. Retraction note to: Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth. 2011;58:883–884. doi: 10.1007/s12630-011-9530-6. [DOI] [PubMed] [Google Scholar]